SynAct Pharma Sharpens Phase III Plans for Resomelagon
SynAct Pharma has refined its plans for a Phase III trial of resomelagon.
Related stories
Meta Set to Raise $15 Billion From US Dollar Bond Sale
M impact | EQUITY | Nov 03, 2026, 07:32 PM UTC
Invesco Reports Third-Quarter Revenue of $1.87 Billion
Invesco reported revenue of $1.87 billion, up 14.2% year over year. Net income attributable to the company declined 2.3% to $294.5 million, while diluted EPS fell to $0.65 from $0.
M impact | EQUITY | Nov 03, 2026, 07:31 PM UTC
GPODS Reports $107,175 Third-Quarter Net Loss
GPODS reported a net loss of $107,175 for the quarter ended September 30, 2026, narrowed from $123,515 a year earlier. Diluted EPS was $(0.01) in both periods, with no product sale
M impact | EQUITY | Nov 03, 2026, 07:31 PM UTC
US session market picture: S&P 500 +0.44%, Nasdaq 100 +0.78%; EUR/USD +0.05%, WTI -0.47%, WBD leads volume
US session market picture. US index futures: S and P futures is up 0.44 percent, Nasdaq futures is up 0.78 percent, Dow futures is down 0.33 percent and Russell futures is up 0.58
M impact | EQUITY | Nov 03, 2026, 07:30 PM UTC
Nasdaq Composite Rises More Than 1% in Afternoon Trading
The index is looking to break a three-session losing streak as investors shift attention from earnings to the U.S. midterm elections.
M impact | EQUITY | Nov 03, 2026, 07:28 PM UTC
US Restrictions Complicate SK Hynix’s New York Chip Plans
US officials have held up approval for chipmaking equipment SK Hynix needs to expand production in China, complicating plans for new memory-chip plants in New York, people familiar
L impact | EQUITY | Nov 03, 2026, 07:25 PM UTC